Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012

AIDS

Volumn 27, Issue 16, 2013, Pages 2567-2575

  Cohen, Sophie ^a   Smit, Colette ^b   Van Rossum, Annemarie M C ^c   Fraaij, Pieter L A ^c   Wolfs, Tom F W ^d   Geelen, Sibyl P M ^d   Schölvinck, Elisabeth H ^e   Warris, Adilia ^f   Scherpbier, Henriette J ^a   Pajkrt, Dasja ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b STICHTING HIV MONITORING   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antiretroviral therapy; children; HIV; immunological reconstitution; mortality; the Netherlands; vertical transmission; virological response

Indexed keywords

EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; COHORT ANALYSIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; OUTCOME ASSESSMENT; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; NETHERLANDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84885430155     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432451.75980.1b     Document Type: Article

References (52)

1. Sighem A van, Smit C, Gras L, Holman R, Stolte I, Prins M, et al. HIV Monitoring Report; 1 November 2011. DTP, studio Zest, Zaandam; 2011.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
3. Gibb DM, Duong T, Tookey P, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327:1019-1025.
4. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522-1528.
5. De Martino M, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P. Reduction in mortality with availability of antire-troviral therapy for children with perinatal HIV-1 infection. JAMA 2000; 284:190-197.
6. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, Firtion G, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39:1692-1698.
7. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 2005; 293:2221-2231.
8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
9. Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23:597-604.
10. Newell ML, Patel D, Goetghebuer T, Thorne C. CD4R cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis 2006; 193:954-962.
11. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Geneva: Switzerland: WHO; 2010.
12. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006; 41:504-508.
13. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243.
14. Lewis J, Walker S, Castro H, De Rossi A, Gibb DM, Giaquinto C, et al. Age and CD4R count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis 2012; 205:548-556.
15. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J 2009; 28:488-492.
16. Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Bernardi S, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis 2009; 9:140-146.
17. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, Zissis G, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003; 22:62-69.
18. Van Rossum AMC, Scherpbier HJ, Van Lochem EG, Pakker NG, Slieker WAT, Wolthers KC, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 2001; 15:2267-2275.
19. Comans-Bitter WM, De Groot R, Van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130:388-393.
20. Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voricona-zole. Clin Infect Dis 2003; 37:828-830.
21. Boer K, Smit C, Van der Flier M, De Wolf F. The comparison of the performance of two screening strategies identifying newly-diagnosed HIV during pregnancy. Eur J Public Health 2011; 21:632-637.
22. Macassa E, Burgard M, Veber F, Picard C, Neven B, Malhaoui N, et al. Characteristics of HIV-infected children recently diagnosed in Paris, France. Eur J Pediatr 2006; 165:684-687.
23. Goetghebuer T, Haelterman E, Marvillet I, Barlow P, Hainaut M, Salameh A, et al. Vertical transmission of HIV in Belgium: a 1986-2002 retrospective analysis. Eur J Pediatr 2009; 168:79-85.
24. Giraudon I, Forde J, Maguire H, Arnold J, Permalloo N. Antenatal screening and prevalence of infection: surveillance in London, 2000-2007. Eurosurveillance 2007; 14:1-5.
25. Del Amo J, Likatavičius G, Pérez-Cachafeiro S, Hernando V, González C, Jarrín I, et al. The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999-2006. Eur J Public Health 2011; 21:620-626.
26. Naver L, Lindgren S, Belfrage E, Gyllensten K, Lidman K, Gisslen M, et al. Children born to HIV-1-infected women in trends in epidemiology and vertical transmission. J Acquir Immune Defic Syndr 2006; 42:484-489.
27. Schmid J, Jensen-Fangel S, Valerius NH, Nielsen VR, Herlin T, Christensen HO, et al. Demographics in HIV-infected children in Denmark: results from the Danish Paediatric HIV Cohort Study. Scand J Infect Dis 2005; 37:344-349.
28. Chiappini E, Galli L, Lisi C, Gabiano C, Giaquinto C, Giacomet V, et al. Risk of perinatal HIV infection in infants born in Italy to immigrant mothers. Clin Infect Dis 2011; 53:310-313.
29. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924.
30. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.N EnglJ Med 1997; 336:1337-1342.
31. Ghosh RK, Ghosh SM, Chawla S. Recent advances in antire-troviral drugs. Exp Opin Pharmacother 2011; 12:31-46.
32. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PloS One 2011; 6:e22003.
33. Martinez E, Nelson M. Simplification of antiretroviral therapy with etravirine. AIDS Rev 2010; 12:52-59.
34. Fraaij PLA, Verweel G, Van Rossum AMC, Hartwig NG, Burger DM, De Groot R. Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. Infection 2007; 35:186-189.
35. Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007; 119:e705-e715.
36. Van der Flier M, Verweel G, Van der Knaap LC, Van Jaarsveld P, Driessen GJ, Van der Lee M, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. Antivir Ther 2008; 13:1087-1090.
37. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, thymopoiesis, and CD4RR T-lym-phocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143-149.
38. Clerici M, Saresella M, Trabattoni D, Ferrante P, Vanzulli A, Vigano A. Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2002; 16:2219-2221.
39. Walker S, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-1924.
40. Patel K, Hernán M, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, et al. Long-term effects of highly active antiretroviral therapy on CD4RR cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008; 46:1751-1760.
41. Newell ML, Patel D, Goetghebuer T, Thorne C. CD4R cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis 2006; 193:954-962.
42. Soh C, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4R T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003; 362:2045-2051.
43. Van Rossum AMC, Geelen SPM, Hartwig NG, Wolfs TFW, Weemaes CMR, Scherpbier HJ, et al. Results of 2 years of treatment with protease-inhibitor- containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34:1008-1016.
44. The Collaboration of Observational HIV Epidemiological Research (COHERE Study Group). Response to combination antiretroviral therapy: variation by age. AIDS 2008:1463-1473.
45. Mofenson LM, Korelitz J, Meyer WA, Bethel J, Rich K, Pahwa S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4R lymphocyte percentage, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clin. J Infect Dis 1997; 175:1029-1038.
46. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Predictive value of quantitative plasma HIV RNA and CD4RR lymphocyte count in HIV-infected infants and children. JAMA 1998; 279:756-761.
47. Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Giacomet V, et al. Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period. Acta Paediatr 2012; 101:e287-e295.
48. Palladino C, Climent FJ, De José MI, Jimenez De Ory S, Bellón JM, Guillén S, et al. Causes of death in pediatric patients vertically infected by the human immunodeficiency virus type 1 in Madrid, Spain, from 1982 to mid-2009. Pediatr Infect Dis J 2011; 30:495-500.
49. Van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21:743-747.
50. Fraaij PLA, Rakhmanina N, Burger DM, De Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Therapeut Drug Monit 2004; 26:122-126.
51. Van der Plas A, Scherpbier H, Kuijpers T, Pajkrt D. The effect of different intervention programs on treatment adherence of HIV-infected children, a retrospective study. AIDS Care 2012; 24:37-41.
52. Mahdavi S, Malyuta R, Semenenko I, Pilipenko T, Thorne C. Treatment and disease progression in a birth cohort of vertically HIV-1 infected children in Ukraine. BMC Pediatr 2010; 10:85-94.